Company intelligence
Ncardia
Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster.
About Ncardia
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications. Explore our website to learn more www.ncardia.com.
Verified activity
Signals from Ncardia
2 published signals
Presence & Recognition
Ncardia hosted the Drafts & Discoveries event in South San Francisco on 8 October 2026 featuring scientific talks, open discussion, and networking across cell engineering, protein degradation, and next-generation drug discovery.
Reported by Ncardia
Products & Services
Ncardia launched the Ncyte IO Safety Panel, a single workflow that combines human iPSC-derived neurons, cardiomyocytes, endothelial cells, melanocytes, hepatocytes, intestinal epithelial cells, and alveolar epithelial cells to compare functional toxicity across multiple tissues.
Reported by Ncardia